A meta-research study revealed several challenges in obtaining placebos for investigator-initiated drug trials
Speich B. et al, (2021), Journal of Clinical Epidemiology, 131, 70 - 78
Quality of life in the FOXFIRE, SIRFLOX and FOXFIRE-global randomised trials of selective internal radiotherapy for metastatic colorectal cancer
Wolstenholme J. et al, (2020), International Journal of Cancer, 147, 1078 - 1085
Ophthalmic statistics note 14: Method agreement studies in ophthalmology: The intraclass correlation coefficient?
Bunce C. et al, (2020), British Journal of Ophthalmology, 104, 1033 - 1035
Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma
Thomas A. et al, (2020), European Journal of Cancer, 124, 131 - 141
Cytosponge™ for post-chemoradiation surveillance of oesophageal cancer: a feasibility study
Levy S. et al, (2019), Annals of oncology : official journal of the European Society for Medical Oncology, 30
Validation of Electronic Visual Acuity Measurement Against Standardised ETDRS Charts In Retinal Disease
Jolly JK. et al, (2019), INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 60
A phase I first-in-human, dose-escalation and expansion study to evaluate the safety and tolerability of NUC-3373 in patients with locally advanced, unresectable or metastatic solid malignancies
Blagden S. et al, (2018), Annals of oncology : official journal of the European Society for Medical Oncology, 29
Patients’ intention to consume prescribed and non-prescribed medicines: A study based on the theory of planned behaviour in selected European countries
Kamekis A. et al, (2018), Journal of Clinical Pharmacy and Therapeutics, 43, 26 - 35
A Phase I dose-finding and safety study of AZD8931 with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma: the randomised expansion phase of the DEBIOC trial
Thomas A. et al, (2018), BRITISH JOURNAL OF CANCER, 119, 37 - 38
Adequate SIRT activity dose is as important as adequate chemotherapy dose – Authors' reply
Sharma RA. et al, (2017), The Lancet Oncology, 18
Overall survival in the FOXFIRE-SIRFLOX-FOXFIRE global prospective randomized studies of first-line SIRT in patients with mCRC
Wasan H. et al, (2017), Annals of Oncology, 28, x43 - x44
Quality of life in patients with liver metastases from colorectal cancer treated with first-line selective internal radiotherapy (SIRT): EQ-5D, EORTC QLQ-C30 and LMC21 results from the FOXFIRE study
Wolstenholme J. et al, (2017), European Journal of Surgical Oncology, 43, 2234 - 2234
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials
Wasan HS. et al, (2017), The Lancet Oncology, 18, 1159 - 1171
SELECTIVE INTERNAL RADIOTHERAPY (SIRT) IN METASTATIC COLORECTAL CANCER PATIENTS WITH LIVER METASTASES: PRELIMINARY PRIMARY CARE RESOURCE USE AND UTILITY RESULTS FROM THE FOXFIRE RANDOMISED CONTROLLED TRIAL
Fusco R. et al, (2017), VALUE IN HEALTH, 20, A445 - A446
Toxoplasmosis in female high school students, pregnant women and ruminants in Cyprus
Liassides M. et al, (2016), Transactions of the Royal Society of Tropical Medicine and Hygiene, 110, 359 - 366
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013
Forouzanfar MH. et al, (2015), The Lancet, 386, 2287 - 2323
Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: Quantifying the epidemiological transition
Murray CJL. et al, (2015), The Lancet, 386, 2145 - 2191